Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...